Charles is biotx.ai CTO. With his PhD and Post-Doc in Computational Genomics from the University of Cambridge, he excellently ties together Marco's personalised drug development knowledge and Joern's machine learning background. \In addition to his outstanding academic contributions, Charles published in Nature, he is a software development veteran. Charles took the prototypes that Joern built and turned them into production quality software that scales to the platform level.